Long-lasting severe immune dysfunction in Ebola virus disease survivors

Aurélie Wiedemann, Emile Foucat, Hakim Hocini, Cécile Lefebvre, Boris P. Hejblum, Mélany Durand, Miriam Krüger, Alpha Kabinet Kéita, Ahidjo Ayouba, Stéphane Mély, José-Carlos Fernandez, Abdoulaye Touré, Slim Fourati, Claire Lévy‐Marchal, Hervé Raoul, Éric Delaporte, Lamine Koivogui, Rodolphe Thiébaut, Christine Lacabaratz, Yves Lévy, Laura MarchNature Communications 2020 · DOI

Abstract

Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18-25]) after discharge from treatment center. Compared with healthy donors, EBOV_S exhibit increases of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and a depletion of circulating dendritic cells. All survivors have EBOV-specific IgG antibodies and robust and polyfunctional EBOV-specific memory T-cell responses. Deep sequencing of the genes expressed in blood reveals an enrichment in 'inflammation' and 'antiviral' pathways. Integrated analyses identify specific immune markers associated with the persistence of clinical symptoms. This study identifies a set of biological and genetic markers that could be used to define a signature of "chronic Ebola virus disease (CEVD)".

Introduction

While the acute phase of Ebola virus disease (EVD) is characterized by high mortality and intense viral replication, the long-term health consequences for survivors have remained largely uncharacterized. Thousands of survivors from the 2013–2016 West African outbreak continue to report lingering symptoms—such as extreme fatigue, joint pain, and ocular issues—collectively known as "post-Ebola syndrome."

This study sought to determine whether these symptoms reflect a slow recovery or a fundamental, long-lasting shift in the immune system. By employing a multi-omics approach—combining proteomics, flow cytometry, and transcriptomics—researchers analyzed 35 Guinean survivors at a median of 23 months post-discharge, comparing them against 39 healthy local controls (HD) to identify biomarkers of this persistent clinical state.

Results

Persistent Systemic Inflammation and "Leaky Gut"

A primary finding of the study is the presence of chronic systemic inflammation nearly two years after viral clearance. Survivors exhibited significantly higher levels of pro-inflammatory cytokines, including IL-8 and TNF-α, compared to healthy donors.

Crucially, the data suggests that this inflammation may be driven by long-term damage to the intestinal barrier. Elevated levels of intestinal fatty acid-binding protein (iFABP), soluble CD14 (sCD14), and Lipopolysaccharide-binding protein (LBP) were observed in survivors. These markers indicate a "leaky gut" phenotype, where microbial products translocation from the gut into the bloodstream likely maintains the immune system in a state of chronic activation.

Quantification of serum-soluble mediators showing elevated inflammation and gut damage markers in survivors.

Immune Cell Dysregulation and the CEVD Signature

Beyond soluble markers, the cellular immune profile of survivors showed significant alterations. A hallmark of this dysfunction is the persistent depletion of plasmacytoid dendritic cells (pDCs), which are essential for initiating antiviral responses. Survivors also displayed signs of "battle fatigue" in their adaptive immune system, with B cells showing markers of exhaustion and T cells remaining abnormally activated, similar to profiles seen in chronic infections like HIV or autoimmune disorders like Systemic Lupus Erythematosus (SLE).

Modifications in immune cell subsets, highlighting the depletion of dendritic cells (pDCs) and activation of T cells in survivors.

Integrated analysis identified a specific biological signature—characterized by low pDC frequency, high nonclassical NK cells, and elevated sCD163—that statistically correlates with the persistence of clinical symptoms. This signature defines what the authors term "chronic Ebola virus disease" (CEVD).

Transcriptomic "Echo" and Robust Memory

Whole-blood RNA sequencing revealed that genes involved in interferon signaling and antiviral defense remained upregulated long after the virus was undetectable. Despite this chronic dysregulation, the adaptive immune system maintained a silver lining: all survivors exhibited robust, polyfunctional memory T-cell responses specifically targeted at Ebola proteins, suggesting strong long-term protection against reinfection.

Discussion

This study demonstrates that EVD is not merely an acute infection but can transition into a chronic condition characterized by systemic inflammation and immune exhaustion. The correlation between "leaky gut" markers and chronic activation provides a potential mechanistic target for future therapies.

While the study is limited by its cross-sectional nature and small cohort size, it provides a critical framework for understanding the biological basis of post-Ebola syndrome. Future longitudinal research is required to determine if these immune alterations eventually resolve or if they predispose survivors to premature immune aging and other health complications.

Summary updated

Abstract

Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18-25]) after discharge from treatment center. Compared with healthy donors, EBOV_S exhibit increases of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and a depletion of circulating dendritic cells. All survivors have EBOV-specific IgG antibodies and robust and polyfunctional EBOV-specific memory T-cell responses. Deep sequencing of the genes expressed in blood reveals an enrichment in 'inflammation' and 'antiviral' pathways. Integrated analyses identify specific immune markers associated with the persistence of clinical symptoms. This study identifies a set of biological and genetic markers that could be used to define a signature of "chronic Ebola virus disease (CEVD)".
BibTeX
@inproceedings{wiedemann2020long,
  author = {Aurélie Wiedemann and Emile Foucat and Hakim Hocini and Cécile Lefebvre and Boris P. Hejblum and Mélany Durand and Miriam Krüger and Alpha Kabinet Kéita and Ahidjo Ayouba and Stéphane Mély and José-Carlos Fernandez and Abdoulaye Touré and Slim Fourati and Claire Lévy‐Marchal and Hervé Raoul and Éric Delaporte and Lamine Koivogui and Rodolphe Thiébaut and Christine Lacabaratz and Yves Lévy and Ahidjo Ayouba and Éric Delaporte and Alpha Kabinet Kéita and Lamine Koivogui and Christine Lacabaratz and Laura March and Yves Lévy and Hervé Raoul and Abdoulaye Touré and Abdoulaye Touré},
  title = {{Long-lasting severe immune dysfunction in Ebola virus disease survivors}},
  booktitle = {Nature Communications},
  year = {2020},
  doi = {10.1038/s41467-020-17489-7},
}
Figure